The House of Representatives rejected an amendment on Thursday that would have removed an existing rider that scientists say inhibits research into the therapeutic potential of Schedule I controlled substances such as psilocybin, MDMA and marijuana.
The amendment, introduced by Rep. Alexandria Ocasio-Cortez (D-NY) last week, would have eliminated a section of a large-scale appropriations bill stipulating that no federal dollars can be spent on “any activity that promotes the legalization of any drug or other substance in Schedule I.”
The presiding officer ruled that the measure was approved in a voice vote after the debate early Thursday morning, but that was reversed during a later roll call vote of 91 to 331.
“Academics and scientists report that provisions like this create [stigma] and insurmountable logistical hurdles to researching schedule I drugs like psilocybin and MDMA which have shown promise in end of life therapy and treating PTSD,” a summary of the amendment states.
The House Rules Committee cleared the proposal for floor consideration before the full chamber on Monday. However, during the same meeting it blocked a separate amendment that would have barred the Department of Education from denying or limiting funds to universities that allow the use or possession of medical cannabis on campus in a legal state.
Ocasio-Cortez’s measure was cosponsored by Reps. Lou Correa (D-NY), Ro Khanna (D-CA) and Matt Gaetz (R-FL).
“I’m a strong believer in evidence-based policymaking,” Ocasio-Cortez said during the floor debate. “And wherever there is evidence of good, we have a moral obligation to pursue and explore the parameters of that good. Even if it means challenging our past assumptions or admitting past wrongs.”
Yesterday I offered an amendment to allow Fed researchers to study Schedule I Drugs, incl:
– MDMA & PTSD
– Psilocybin & severe depression
– Ibogaine & opioid withdrawal
🚨 House votes TODAY.
If you’re supportive, CALL YOUR REP. Don’t assume they’ll vote for it – let them know. https://t.co/NrVoxKQa2X
— Alexandria Ocasio-Cortez (@AOC) June 13, 2019
Describing the current situation researchers face as a “catch-22,” she said that the problem with the current policy is that it is “so vague and broadly interrupted that it prevents scientists from researching, examining and exploring avenues of treatment that could alleviate an enormous amount of suffering from medical conditions.”
Correa also spoke in support.
“We need legitimate, reliable research by universities and other institutions into the health benefits of cannabis and other substances,” he said. “This amendment will allow credible research institutions to conduct research by removing layers of paperwork that serve as hurdles meant to block such research. As more Americans, including veterans, use cannabis and so-called ‘magic mushrooms’ to manage or treat their pain or other health conditions, it’s important that doctors have the necessary information on the possible benefits, or not, of these substances.”
Correa called the amendment “both timely and very necessary” in light of recent local moves to reform criminal policies dealing with psychedelics.
Voters in Denver approved a local measure to decriminalize the substance last month, and the Oakland City Council unanimously passed a similar measure last week that also applies to other psychedelics including ayahuasca, mescaline and ibogaine.
Both Correa and Ocasio-Cortez spoke about the suicide rate among military veterans and the potential of psychedelics to help them with conditions such as post-traumatic stress disorder.
This bill has bipartisan support, but it also has bipartisan opposition.
Many Dem & GOP alike, are uncomfortable w/ letting federal researchers merely *study* the clinical promise of certain drugs – even in veteran PTSD.
Your call can help them see a shift in public sentiment.
— Alexandria Ocasio-Cortez (@AOC) June 13, 2019
“Thirty percent of all military veterans have considered suicide. If a substance shows promise in treating PTSD, we have an obligation to study it,” Ocasio-Cortez said. “One of the leading causes of death in America today is suicide. So if a Schedule I drug shows clinical promise in treating and in treatment resistant depression, perhaps it is not the drug we should say morally wrong, but perhaps it is the law, the schedule, the statute.”
But Rep. Andy Harris (R-MD) rose to oppose the amendment, saying that it wouldn’t actually help to foster research, a goal he said he shares.
“The bottom line is, this is not the place and this won’t do what the authors in support of the amendment say it’s going to do. The fact of the matter is that the DEA is the one that enforces the classification of Schedule I. This bill does nothing to do with the DEA,” he argued. “The problem lies in the fact that it is a Schedule I drug and the appropriate way to deal with this is through an authorizing committee.”
A longtime opponent of legalization, Harris suggested that cannabis “induces psychosis in young people,” adding that it is “a gateway drug.”
The amendment, he said, “sends a bad signal” and isn’t just about marijuana. “It’s about every Schedule I drug. And there are very dangerous schedule 1 drugs.”
Rep. Scott Perry (R-PA) also spoke against the proposal.
“Do we want the federal government telling our families and our children, take this, it’s good for you?” he asked. “Maybe it is. I sure don’t think it is. I certainly don’t want my kids taking it and I don’t want the government promoting it.”
Citing the growing political support for marijuana reform at a time when tobacco use rates are at historic lows, Perry said, “now we’re going to tell the rest of the country, ‘let’s all start smoking marijuana instead.”
“I don’t think this is what the government should be promoting,” he said.
But Ocasio-Cortez argued that her amendment has bipartisan appeal.
“My colleagues on the other side of the aisle often bemoan the role of government and promote ideas of choice. And here I am happy in that spirit to agree,” she said. “We should get government and political opinion out of scientific research when we have seen and shown promise in a way that can help people and their medical needs.”
“I understand that the politics of this bill may make it difficult for some to support right now,” she said. “But I propose this amendment and urge my colleagues to support it because politics isn’t always about winning today, but it is about fighting for what is right in the future and for future generations.”
If Ocasio-Cortez’s amendment had passed through the House, and deleted from that chamber’s bill the longstanding prohibition on advocating legalization that was first enacted in 1996, that wouldn’t have necessarily meant that the rider would have ultimately been removed from federal law. The Senate Appropriations Committee has not yet introduced its version of the funding legislation.
The last few weeks has seen a significant uptick in cannabis reform being pursued through the congressional appropriations process, with multiple committee reports urging the adoption on marijuana legislation. Committees have called for provisions on regulating CBD, implementing hemp policies, lifting barriers to cannabis research, preventing impaired driving, protecting veteran benefits and requesting that the federal government reconsider its employment policies as it relates to federal workers who use cannabis in compliance with state laws.
On Tuesday, the House Appropriations Committee approved a spending bill that includes a section providing protections for banks that service state-legal marijuana business and also remove a longstanding rider that has blocked Washington, D.C. from using its own local tax dollars to legalize and regulate cannabis sales.
Update: This story has been updated to include information about the roll call vote on the amendment.
Photo courtesy of Rick Proctor.
California Governor Signs Marijuana Tax Fairness Bill But Vetoes Cannabis In Hospitals
California Gov. Gavin Newsom (D) announced on Saturday that he signed several marijuana-related bills into law—including one that will let legal businesses take advantage of more tax deductions—but also vetoed another measure that would have allowed some patients to use medical cannabis in health care facilities.
Under a section of current federal law known as 280E, marijuana growers, processors and sellers are unable to deduct expenses from their taxes that businesses in any other sector would be able to write off. Until now, California policy simply mirrored the federal approach.
(Marijuana Moment’s editor provides some content to Forbes via a temporary exclusive publishing license arrangement.)
Photo courtesy of Carlos Gracia.
Former FDA Head Floats Federal Marijuana Regulation ‘Compromise’ To Address Vaping Issue
Former Food and Drug Administration (FDA) Commissioner Scott Gottlieb seems to propose changing the scheduling status of marijuana under federal law as a “compromise” to provide limited regulations and promote research.
In an op-ed published in The Wall Street Journal on Friday, Gottlieb said the recent spike in vaping-related lung injuries involving contaminated THC cartridges demonstrates the need for federal regulations.
While he expressed frustration over the “federal government’s decade-long refusal to challenge state laws legalizing pot,” he also recognized that enforcing prohibition in legal states isn’t politically practical and floated a “feasible compromise” that would “require Congress to take marijuana out of the existing paradigm for drug scheduling, especially if Congress wants to allow carefully regulated access for uses that fall outside FDA-approved drug indications.”
That language leaves room for interpretation, but he goes on to say that the “ship has probably sailed on legalization for recreational use” and that “regulation of the potency of THC compounds, the forms they take, how they’re manufactured, and who can make purchases ought to be possible.”
Gottlieb stopped short of explicitly backing descheduling, which would represent a formal end to federal prohibition. Still, his recommendation that the government control aspects of legal marijuana markets like THC potency is a more concrete position than he’s taken in recent weeks, where he’s repeatedly bemoaned the lack of regulations and the gap between state and federal cannabis laws as contributing to vaping issues without endorsing a specific policy to correct it.
It’s clear in the editorial that the former commissioner feels Congress has missed its opportunity to prevent the proliferation of state-legal cannabis programs. And he criticized the Obama administration for issuing guidance that offered states some assurances that the Justice Department wouldn’t interfere in their markets, as well as congressional riders barring the department from using its funds to enforce prohibition against medical cannabis patients and providers following state laws.
My Op Ed in today’s @WSJopinion – The tragic vape injuries involving THC demand that we consider a federal reckoning when it comes to the dangerous conflict between state and federal pot laws that leave federal regulators on sidelines https://t.co/HGptTfx8Db
— Scott Gottlieb, MD (@ScottGottliebMD) October 11, 2019
“The result is an impasse,” he wrote. “Federal agencies exert little oversight, and regulation is left to a patchwork of inadequate state agencies. The weak state bodies sanction the adoption of unsafe practices such as vaping concentrates, while allowing an illegal market in cannabis to flourish.”
One area where FDA might be able to exercise its regulatory authority in this grey space would involve oversight of vaping hardware. Because the agency is able to regulate the “components and parts” of vapes for tobacco use—and because companies generally market those products as being intended for the use of vaporizing herbs and concentrates generally—it could be argued that FDA has jurisdiction over regulating the devices. However, that would still prove challenging “without clear laws and firm political support,” Gottlieb said.
My Op Ed in @WSJopinion – The conflict between federal and state law when it comes to marijuana has created a dangerous gap in oversight. It's about time we consider a new federal paradigm when it comes to regulation of cannabis and its active ingredients https://t.co/QifVa5Dbfq
— Scott Gottlieb, MD (@ScottGottliebMD) October 13, 2019
“THC is currently illegal under federal law,” he said. “Right now there’s no middle ground allowing federal agencies to scrutinize these compounds for their manufacturing, marketing and safety.”
Again, it’s not exactly clear what kind of federal regulation Gottlieb is proposing to Congress. He spends part of his op-ed noting the difficulties scientists face in obtaining high quality cannabis for research purposes—an issue that policymakers have indicated rescheduling could resolve—but he also said the government should ensure that any reform move is “backed up with oversight and vigorous enforcement to keep a black market from continuing to flourish and causing these lung injuries.”
That’s led some to assume he’s talking about descheduling and providing for broad regulations, as regulating the market is largely viewed as a primary means of disrupting the illicit market and enforcing safety standards for marijuana products. But the continued ambiguity of his position raises questions about whether he’s actually proposing Congress should go that far.
“The protracted hand-wringing over federal cannabis policy must stop,” he said. “The tragic spate of fatalities related to vaping of pot concentrates means the time has come for Congress and the White House to stop blowing smoke and clear the air.”
Mexican Senate Committees Will Introduce Marijuana Legalization Bill Next Week
Mexican Senate committees will introduce an updated proposal to legalize marijuana for adult use within days.
During a meeting on Thursday, members of the Health, Justice, Public Security and Legislative Studies Committees announced that they would remain in permanent session as they go through various legalization bills that lawmakers have already filed and present a comprehensive new piece of legislation on Thursday.
Sen. Miguel Ángel Navarro Quintero of the ruling MORENA party, who is a cosponsor of one existing reform bill, said the development “is a positive step to regulate—it is definitely a positive step,” according to TV Aztecha.
The primary focus of the committees will be on legislation introduced by Interior Secretary Olga Sánchez Cordero last year, senators said. However, there are about a dozen other legalization bills on the table, including one to have the federal government control the marijuana market, and they said provisions of each proposal would be taken into consideration.
The panels will also look at public input and expert testimony—including a panel led by a former White House drug czar—that were gathered as part of a weeks-long series of cannabis events that the Senate organized.
“It is a backbone that we are taking into account,” Sen. Julio Menchaca of the MORENA party said of Sánchez Cordero’s bill, which the cabinet member filed while previously serving as a senator, adding that “each of the initiatives that different senators have presented are also very important.”
Quintero said “if we are committing an open parliament, all opinions must be taken into account, because if not, we would be simulating a process.”
If the committees are successful in advancing the legislation, that would put the chamber one key step closer to meeting a deadline imposed by the Supreme Court last year. After ruling that the country’s ban on possession and cultivation of cannabis by adults is unconstitutional, it gave lawmakers until the end of October to change federal drug policy.
The leader of the MORENA party in the Senate, Sen. Ricardo Monreal, said earlier this month that the chamber was on track to vote on a legalization bill ahead of that deadline.
Separately, the chairman of the Senate’s Agriculture Committee, Sen. José Narro Céspedes, said on Thursday that legalization will be an economic boon for farmers and must be implemented in a way that disrupts the illicit market.
Photo courtesy of Mike Latimer.